



CD40-mediated activation of the NF- κ B2 pathway

Bruce S. Hostager^{1,2*} and Gail A. Bishop^{2,3,4,5*}

¹ Department of Pediatrics, The University of Iowa, Iowa City, IA, USA

² The Graduate Program in Immunology, The University of Iowa, Iowa City, IA, USA

³ Department of Microbiology, The University of Iowa, Iowa City, IA, USA

⁴ Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA

⁵ Iowa City VA Medical Center, Iowa City, IA, USA

Edited by:

Linda C. Burkly, Biogen Idec, Inc., USA

Reviewed by:

Fulvio D'Acquisto, Queen Mary

University of London, UK

Ellen D. Cahir-McFarland, Biogen

Idec, Inc., USA

*Correspondence:

Bruce S. Hostager, Department of Pediatrics, The University of Iowa, Iowa City, IA 52242, USA

e-mail: bruce-hostager@uiowa.edu;

Gail A. Bishop, Department of

Microbiology, The University of Iowa,

Iowa City, IA 52242, USA

e-mail: gail-bishop@uiowa.edu

CD40 is a critical stimulatory receptor on antigen-presenting cells of the immune system. CD40-mediated activation of B cells is particularly important for normal humoral immune function. Engagement of CD40 by its ligand, CD154, on the surface of activated T cells initiates a variety of signals in B cells including the activation of MAP kinases and NF- κ B. The transcriptional regulator NF- κ B is in reality a family of factors that can promote B cell activation, differentiation, and proliferation. Complex – and only partially understood – biochemical mechanisms allow CD40 to trigger two distinct NF- κ B activation pathways resulting in the activation of canonical (NF- κ B1) and non-canonical (NF- κ B2) NF- κ B. This brief review provides a summary of mechanisms responsible for activation of the latter, which appears to be particularly important for enhancing the viability of B cells at various stages in their life cycle and may also contribute to the development of B cell malignancies. CD40 is also expressed by various cell types in addition to B cells, including T cells, macrophages, dendritic cells, as well as certain non-hematopoietic cells. Here too, while perhaps less extensively studied than in B cells, the CD40-mediated activation of NF- κ B2 also appears to have important roles in cellular physiology.

Keywords: CD40, NF- κ B, signal transduction

The transcriptional regulator NF- κ B participates in many important activation events in B cells, including B cell proliferation and differentiation in response to signaling by tumor necrosis factor receptor (TNFR) family members or toll-like receptor (TLR) proteins (1). NF- κ B is not a single transcription factor, but rather a family of factors composed of homo- and hetero-dimers of p50, p52, c-Rel, RelA (p65), and RelB. Activation of these dimer pairs occurs via two general mechanisms, sometimes referred to as the canonical and non-canonical pathways. Canonical (NF- κ B1) activation is typically rapid as it does not usually require new protein synthesis. Activation of this pathway is mediated largely by degradation of inhibitors present in the cytoplasm, which allows transit of NF- κ B dimers (typically p50/RelA or p50/c-Rel hetero-dimers) into the nucleus. In contrast, activation of non-canonical NF- κ B (NF- κ B2) often occurs after activation of the canonical pathway, may require new protein synthesis, and ultimately results in the nuclear localization of predominantly p52/RelB hetero-dimers, although p52/p65 and p52/c-Rel hetero-dimers have also been described (2). Excellent recent reviews discuss current general models of NF- κ B2 activation (2–5). Briefly, the activation of the NF- κ B2 pathway is largely regulated by the production and posttranslational processing of its precursor, p100. Its proteolytic processing is regulated by I κ B kinase α (IKK α), which is in turn regulated by NF- κ B-inducing kinase (NIK).

CD40-MEDIATED NF- κ B2 ACTIVATION IN B CELLS

CD40 signaling in B cells can modulate the activation of NF- κ B2 at several points. First, CD40 signaling strongly activates NF- κ B1

in B cells. This activation leads to the enhanced production of p100 (4). In addition, CD40 can regulate the posttranslational processing of p100 by regulating the activity of NIK (6). In resting cells, NIK activity is inhibited by a protein complex that includes TNFR-associated factor (TRAF)2, TRAF3, and cellular inhibitors of apoptosis (cIAP)1/2 (5). The major function of this complex appears to be in mediating the ubiquitination and degradation of NIK in resting B cells. Within the complex, TRAF3 appears to interact with NIK, while TRAF2 mediates interactions between TRAF3 and the cIAP molecules. Engagement of CD40 by its ligand leads to recruitment of TRAF proteins, including TRAFs 2 and 3, to the cytoplasmic domain of CD40. This event disrupts the NIK regulatory function of the TRAF2/TRAF3/cIAP complex, perhaps by promoting the ubiquitination, and degradation of TRAF3. With disruption of the NIK regulatory complex, NIK begins to accumulate (via new protein synthesis) in the cytoplasm to levels where it promotes the phosphorylation and activation of IKK α . In turn, IKK α activity mediates the phosphorylation of p100, which targets the protein for processing by the proteasome, resulting in p52 production (3–5).

A number of genetically modified mouse strains and cell lines have contributed to our understanding of NF- κ B2 regulation by CD40 in B cells (7–11). TRAF2, TRAF3, and TRAF6 all significantly contribute to this CD40 signal transduction. Mouse B cell lines deficient in TRAF2 or TRAF6 exhibit little or no defect in CD40-mediated NF- κ B2 activation (10). However, B cell lines doubly deficient in TRAF2 and TRAF6 appear defective in the activation of NF- κ B2, suggesting that the two molecules have

overlapping functions in the activation of this pathway. Potentially, these results are explained by the ability of CD40, through TRAF2 and TRAF6, to activate the NF- κ B1 pathway, which in turn activates p100 transcription. Primary B cells from TRAF2-deficient mice exhibit elevated basal NF- κ B2 activation (not observed in the cell line studies), which is only weakly augmented by CD40 signaling (9), consistent with a role for TRAF2 in the NIK regulatory complex. In the cell line studies, TRAF2 deficiency did not appear to augment the basal level of p52 production (10), although this may have been due to limited production of p100 in non-activated cells. B cells from mice conditionally deficient in TRAF3 specifically in B cells also exhibit strong constitutive activation of the NF- κ B2 pathway (7, 11), which is again consistent with the model in which TRAF3 is a major component of the NIK regulatory complex. While the phenotypes of TRAF2-, cIAP-, and TRAF3-deficient primary B cells are somewhat similar with respect to the constitutive activation of NF- κ B2, there are instructive differences between the strains [reviewed in (5)]. CD40-mediated differentiation of B cells into germinal center B cells is augmented in TRAF3-deficient mice (7, 11), but TRAF2- or cIAP-deficient mice have a significant defect in germinal center B cell development (8). This likely reflects the role of TRAF2/cIAP in activation of the NF- κ B1 pathway, which TRAF3 does not share.

Interestingly, in B cell-specific TRAF3-deficient mice, the elevated constitutive activation of NF- κ B2 can be enhanced somewhat by CD40 stimulation (11), indicating the existence of TRAF3-independent mechanisms of NIK/NF- κ B2 regulation. This possibility is further supported by the observation that CD40 signaling can activate NF- κ B2 in TRAF3-deficient B cell lines reconstituted with a mutant TRAF3 molecule that binds NIK robustly, but is not degraded following CD40 stimulation (Lin et al., this issue). These observations demonstrate that the regulation of NF- κ B2 by CD40 in B cells is only partially understood. Recently, the protein kinase TANK-binding kinase 1 (TBK1) was shown to negatively regulate NF- κ B2 activation and IgA Ig isotype switching in primary B cells, potentially through phosphorylation/degradation of NIK (12). The de-ubiquitinating enzyme OTUD7B was also shown recently to potentially negatively regulate NF- κ B2 (and primary B cell activation) by inhibiting activation-induced degradation of TRAF3 (13). Additionally, zinc finger protein 91 has recently been shown to promote NIK stability in a CD40-stimulated epithelial tumor cell line, perhaps through K63-linked polyubiquitination of NIK (14). Whether this mechanism is relevant to the CD40-mediated activation of B cells remains to be demonstrated. It is likely that additional regulatory mechanisms will come to light in the next few years, and will contribute to our understanding of normal B cell biology as well as the physiology of B cell malignancies.

CD40-MEDIATED NF- κ B2 ACTIVATION IN NON-B CELLS

Compared to the extensive research performed in B cells, a cell type in which NF- κ B activation is a major regulatory pathway, relatively little investigation has been performed on CD40-mediated NF- κ B2 signaling in other cell types. Most studies of CD40 functions in non-B cells do not examine NF- κ B activation. In those

that do, canonical NF- κ B1 activation is typically the focus, and/or methods used (reporter gene activation or electrophoretic mobility shift assay, EMSA) do not allow results to distinguish between NF- κ B1 and NF- κ B2 induction. We summarize below the information that is currently available on CD40-mediated induction of the NF- κ B2 pathway in non-B cells.

OTHER HEMATOPOIETIC CELLS

T lymphocytes

The physiologic importance of direct signaling to T cells by CD40 has at times been a controversial topic (15). However, there is no doubt that normal activated CD4⁺ and CD8⁺ T cells can express CD40, and it appears to play significant biological roles in mouse models of T cell-dependent immune responses (16, 17), including autoimmune responses [reviewed in Ref. (15)]. However, the role of CD40-mediated NF- κ B activation, and in particular NF- κ B2 activation in these roles is unclear, and may be context-dependent. CD3⁺CD8⁺CD40⁺ T cells in Balb/c mice exhibit cytotoxic activity toward CD4⁺CD25⁺ T regulatory cells during *Leishmania* infection – this activity is CD40-dependent, but unaffected by inhibitors of NF- κ B (18). A CD4⁺ mouse T cell line stably expressing transfected CD40 utilizes CD40 as an effective co-stimulatory signal with T cell receptor signals to activate T cell functions. In this model, both NF- κ B1 and NF- κ B2 pathways in T cells are activated by CD40 (19). The ultimate biological importance of NF- κ B2 activation in T cell CD40 signaling remains to be explored.

Myeloid cells

Monocytes and macrophages, like B cells, constitutively express CD40, which activates mitogen-activated protein (MAP) kinases and NF- κ B in these cells [reviewed in Ref. (20)]. However, very little is known about the potential involvement of the NF- κ B2 pathway in macrophage CD40 signaling. Revy et al. performed a direct comparison between human monocytes and B cells activated through CD40. EMSA demonstrated that nuclear translocation of NF- κ B binding activity is induced by CD40 in both cell types, and the p50 subunit involved in NF- κ B1 activation is part of these nuclear complexes. Interestingly, the p65 subunit was only present in complexes from B cells (21). However, as the CD40 stimulation was only of short duration in these experiments (30 min); the activation of NF- κ B2 was not assessed at later times.

CD40 also delivers potent and important signals to dendritic cells (DC) [reviewed in Ref. (22)]. Following signals from CD40 that stimulate the ability of DC to cross-present antigen to T cells, the nuclear translocation of p52 characteristic of NF- κ B2 signaling is seen. Mice bearing a mutant NIK that disrupts NF- κ B2 activation by various signals, the NIK^{aly/aly} mouse, show DC functional defects (23). CD40 fails to induce cross presentation of antigens to CD8 T cells in the NIK^{aly/aly} mouse, implicating NF- κ B2 in this particular DC function. However, the evidence is indirect, as the NIK mutation is expressed in all cells of the mouse, and will impact multiple pathways of cell development and function. In another experimental model, human monocyte-derived DC treated with siRNA for NIK or IKK α are unable to produce the cytokines IDO and IL-6 following *in vitro* stimulation with the CD40 ligand, CD154. This also renders the treated DC unable to promote the

induction of T regulatory cells (24). Thus, NF- κ B2 signaling plays important roles in CD40 functions in DC.

NON-HEMATOPOIETIC CELLS

Epithelial cells

CD40 was first described as an antigen expressed on the surface of bladder carcinoma cells (25), and can be expressed on a variety of types of epithelial cells under particular circumstances [reviewed in (26, Lin et al., this issue)]. Unfortunately, by far the most commonly used cells of epithelial origin used to study CD40 signaling are the transformed cell lines HEK 293 and HeLa. In the majority of studies using these cell lines, CD40 and/or the signaling proteins studied are exogenously expressed at highly non-physiologic levels. Thus, because such models can provide misleading results [recently reviewed in (27)], we will not discuss this body of work in this article. Very little is known about the usage of the NF- κ B2 pathway by endogenous CD40 expressed by normal epithelial cells. An interesting report using airway epithelial cells, which produce the cytokine RANTES upon CD40 stimulation, examined NF- κ B activation by EMSA. Nuclear binding complexes for probes with sites characteristic of both NF- κ B1 and NF- κ B2 were identified, with the former peaking at 30 min of stimulation, and the latter at 2 h. The p65 subunit was present in both types of complexes (28). The functional importance of this NF- κ B2 activation remains to be defined.

Fibroblasts

Although CD40 can be expressed by fibroblasts, no information is currently available on the extent or importance of NF- κ B2 activation by CD40 in this cell type. A recent report made the interesting observation that TWEAK, a molecule implicated in various fibrotic processes [reviewed in (29)] inhibits CD40 signaling in the HeLa cell line (30). However, neither fibroblasts nor NF- κ B2 pathways were examined in this study.

Vascular endothelium

It is well-known that CD40 can be expressed on activated endothelium, and its interaction with CD154 has been implicated in the pathogenesis of atherosclerosis [reviewed in Ref. (31)]. A specific role for NF- κ B2 activation has yet to be explored in this CD40 function. In human vascular endothelial cells, stimulation of CD40 with soluble CD154 stimulates the phosphorylation and nuclear translocation of the p65 subunit of NF- κ B at 6 h (32). However, it is unclear whether this represents activation of the NF- κ B2 pathway.

While it is clear that the mechanisms of CD40-mediated NF- κ B activation are complicated (and still incompletely characterized), the consequences of NF- κ B activation in B cells and other cells are orders of magnitude more complex. Many of the genes regulated by NF- κ B have been identified by experiment and by computer analysis, but the work of understanding the subsequent roles of these genes and their interactions in cellular physiology is only in its infancy. Nevertheless, continued characterization of NF- κ B activation mechanisms and consequences of NF- κ B-regulated transcription will lead to a more complete understanding of basic immune system biology as well as the identification of molecular events and interactions that can be exploited in the treatment of immune disorders and cancer.

REFERENCES

- Kaileh M, Sen R. NF- κ B function in B lymphocytes. *Immunol Rev* (2012) **246**:254–71. doi:10.1111/j.1600-065X.2012.01106.x
- Dejardin E. The alternative NF- κ B pathway from biochemistry to biology: pitfalls and promises for future drug development. *Biochem Pharmacol* (2006) **72**:1161–79. doi:10.1016/j.bcp.2006.08.007
- Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF- κ B signaling pathways. *Nat Immunol* (2011) **12**:695–708. doi:10.1038/ni.2065
- Shih VE, Tsui R, Caldwell A, Hoffmann A. A single NF- κ B system for both canonical and non-canonical signaling. *Cell Res* (2011) **21**:86–102. doi:10.1038/cr.2010.161
- Sun SC. The noncanonical NF- κ B pathway. *Immunol Rev* (2012) **246**:125–40. doi:10.1111/j.1600-065X.2011.01088.x
- Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF- κ B-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. *J Biol Chem* (2004) **279**:26243–50. doi:10.1074/jbc.M403286200
- Gardam S, Sierro S, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. *Immunity* (2008) **28**:391–401. doi:10.1016/j.immuni.2008.01.009
- Gardam S, Turner VM, Anderton H, Limaye S, Basten A, Koentgen F, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. *Blood* (2011) **117**:4041–51. doi:10.1182/blood-2010-10-312793
- Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF- κ B activation in mature B cells. *Immunity* (2004) **21**:629–42. doi:10.1016/j.immuni.2004.09.011
- Rowland SR, Tremblay ML, Ellison JM, Stunz LL, Bishop GA, Hostager BS. A novel mechanism for TRAF6-dependent CD40 signaling. *J Immunol* (2007) **179**:4645–53.
- Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. TRAF3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. *Immunity* (2007) **27**:253–67. doi:10.1016/j.immuni.2007.07.012
- Jin J, Xiao Y, Chang J-H, Yu J, Hu H, Starr R, et al. The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF- κ B signaling. *Nat Immunol* (2012) **13**:1101–9. doi:10.1038/ni.2423
- Hu H, Brittain GC, Chang J-H, Puebla-Osorio N, Jin J, Zal A, et al. OTUD7B controls non-canonical NF- κ B activation through deubiquitination of TRAF3. *Nature* (2013) **494**:371–4. doi:10.1038/nature11831
- Jin X, Jin HR, Jung HS, Lee SJ, Lee JH, Lee JJ. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF- κ B-inducing kinase via Lys63-linked ubiquitination. *J Biol Chem* (2010) **285**:30539–47. doi:10.1074/jbc.M110.129551
- Munroe ME. Functional roles for T cell CD40 in infection and autoimmune disease: The role of CD40 in lymphocyte homeostasis. *Sem Immunol* (2009) **21**:283–8. doi:10.1016/j.smim.2009.05.008
- Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. *Science* (2002) **297**:2060–3. doi:10.1126/science.1072615
- Wagner DH, Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. *Proc Natl Acad Sci U S A* (2002) **99**:3782–7. doi:10.1073/pnas.052247099
- Martin S, Pahari S, Sudan R, Saha B. CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory cell function. *J Immunol* (2010) **184**:5510–8. doi:10.4049/jimmunol.0902762
- Munroe ME, Bishop GA. A costimulatory function for T cell CD40. *J Immunol* (2007) **178**:671–82.
- Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. *Sem Immunol* (2009) **21**:257–64. doi:10.1016/j.smim.2009.05.011
- Revy B, Hivroz C, Andreu G, Graber P, Martinache C, Fischer A, et al. Activation of the Jak3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. *J Immunol* (1999) **163**:787–93.
- Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. *Sem Immunol* (2009) **21**:265–72. doi:10.1016/j.smim.2009.05.010
- Lind EF, Ahonen CL, Wasiuk A, Kosaka Y, Becher B, Bennett KA, et al. DC require the NF- κ B2 pathway for cross-presentation of soluble antigens. *J Immunol* (2008) **181**:344–63.

24. Tas SW, Vervoordeldonk MJ, Haji N, Schuitemaker JHN, van der Sluijs KF, May MJ, et al. Noncanonical NF- κ B signaling in DC is required for IDO induction and immune regulation. *Blood* (2007) **110**:1540–9.
25. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. *Cancer Immunol Immunother* (1985) **20**:23–8. doi:10.1007/BF00199769
26. Dugger K, Lowder TW, Tucker TA, Schwiebert LM. Epithelial cells as immune effector cells: the role of CD40. *Sem Immunol* (2009) **21**:289–92. doi:10.1016/j.smim.2009.06.002
27. Gibson TJ, Seiler M, Veitia RA. The transience of transient overexpression. *Nat Methods* (2013) **10**:715–21. doi:10.1038/nmeth.2534
28. Propst SM, Estell K, Schwiebert LM. CD40-mediated activation of NF- κ B in airway epithelial cells. *J Biol Chem* (2002) **277**:37054–63. doi:10.1074/jbc.M205778200
29. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. *Immunol Rev* (2011) **244**:99–114. doi:10.1111/j.1600-065X.2011.01054.x
30. Salzmann S, Lang I, Rosenthal A, Schafer V, Weisenberger D, Carmona Arana JA, et al. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes. *J Immunol* (2013) **191**:2308–18. doi:10.4049/jimmunol.1202899
31. Engel D, Seijkens T, Poggi M, Sanati M, Thevissen L, Beckers L, et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. *Sem Immunol* (2009) **21**:308–12. doi:10.1016/j.smim.2009.06.004
32. Chakrabarti S, Blair P, Freedman JE. CD40-CD40L signaling in vascular inflammation. *J Biol Chem* (2007) **282**:18307–17. doi:10.1074/jbc.M700211200

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 24 September 2013; accepted: 31 October 2013; published online: 15 November 2013.

Citation: Hostager BS and Bishop GA (2013) CD40-mediated activation of the NF- κ B2 pathway. *Front. Immunol.* **4**:376. doi: 10.3389/fimmu.2013.00376

This article was submitted to *Inflammation*, a section of the journal *Frontiers in Immunology*.

Copyright © 2013 Hostager and Bishop. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.